Abstract
The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication
Volume: 15 Issue: 4
Author(s): Eduardo Sobarzo-Sánchez, Seyed Mohammad Nabavi, Eugenio Uriarte and Lourdes Santana
Affiliation:
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Abstract: The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Export Options
About this article
Cite this article as:
Sobarzo-Sánchez Eduardo, Nabavi Mohammad Seyed, Uriarte Eugenio and Santana Lourdes, Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication, Current Topics in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1568026615666150108124533
DOI https://dx.doi.org/10.2174/1568026615666150108124533 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Gene Therapy of Chronic Pain
Current Gene Therapy An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Transport of Drugs Across the Blood-Brain Barrier by Nanoparticles
Current Medicinal Chemistry - Central Nervous System Agents Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Distinct Forms of Spinal Cysticercosis: A Vietnamese Case Series
Current Medical Imaging Cyclooxygenase-2 and Prostaglandin E2 are Associated with Middle Cerebral Artery Occlusion and Hemorrhage in Patients with Moyamoya Disease
Current Neurovascular Research CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Organic Lesions in the Brain MRI of Children with Febrile Seizure
Current Medical Imaging